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Abstract 
Idiopathic Parkinson’s disease (PD) represents a complex interaction between the inherent 
vulnerability of the nigrostriatal dopaminergic system, a possible genetic predisposition, and 
exposure to environmental toxins including inflammatory triggers. Evidence now suggests 
that chronic neuroinflammation is consistently associated with the pathophysiology of PD. 
Activation of microglia and increased levels of pro-inflammatory mediators such as TNF-, 
IL-1 and IL-6, reactive oxygen species and eicosanoids has been reported after post mortem 
analysis of the substantia nigra from PD patients and in animal models of PD. It is 
hypothesised that chronically activated microglia secrete high levels of pro-inflammatory 
mediators which damage neurons and further activate microglia, resulting in a feed forward 
cycle promoting further inflammation and neurodegeneration. Moreover, nigrostriatal 
dopaminergic neurons are more vulnerable to pro-inflammatory and oxidative mediators than 
other cell types because of their low intracellular glutathione concentration. Systemic 
inflammation has also been suggested to contribute to neurodegeneration in PD, as 
lymphocyte infiltration has been observed in brains of PD patients and in animal models of 
PD, substantiating the current theory of a fundamental role of inflammation in 
neurodegeneration. We will examine the current evidence in the literature which offers 
insight into the premise that both central and systemic inflammation may contribute to 
neurodegeneration in PD. We will discuss the emerging possibility of the use of diagnostic 
tools such as imaging technologies for PD patients. Finally, we will present the 
immunomodulatory therapeutic strategies that are now under investigation and in clinical 
trials as potential neuroprotective drugs for PD. 
Keywords: Parkinson’s disease; Neuroinflammation; Systemic inflammation; Microglia; 
Cytokines; Immunomodulatory Therapies 
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1. Parkinson’s disease 
Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder 
after Alzheimer’s disease (AD) with a prevalence of 0.5-1% among people older than 65 
years of age (Toulouse and Sullivan, 2008). The disease is a chronic, progressive 
neurodegenerative motor disorder, resulting in the selective loss of dopaminergic neurons 
within the substantia nigra (SN) pars compacta (pc) of the midbrain. As the disease 
progresses there is gradual circuitry degeneration within the nigrostriatal pathway, producing 
motor, cognitive and psychiatric symptoms (Braak et al., 2003). Despite intensive research 
the aetiology of this neurodegenerative disease still remains unclear with ~10% of cases with 
a clear genetic origin while the rest are of idiopathic origin although a number of risk factors 
have been identified including age, genetic predisposition, environmental toxins, neuronal 
injury such as traumatic brain injury (TBI) or stroke, and bacterial or viral infections (Bekris 
et al., 2010; Koprich et al., 2008; Tansey and Goldberg, 2010).  The most significant 
environmental factors implicated in idiopathic PD are pesticides and have been shown to 
induce oxidative stress which leads to increased lipid peroxidation, DNA damage, 
mitochondrial dysfunction and ultimately dopaminergic neuronal dysfunction in the SNpc 
(Dick, 2006; Jenner, 2003). Nigral dopaminergic neurons are particularly vulnerable to 
oxidative stress as they operate under high oxidant conditions due to reduced levels of the 
anti-oxidant glutathione and increased nigral iron content (Dexter et al., 1989; Misra and 
Kalita, 2010; Sian et al., 1994). Oxidative stress is also a key stimulator of microglial 
activation, which subsequently leads to the generation of reactive oxygen species (ROS) from 
microglia, and consequently further dopaminergic neuronal death to ultimately propagate and 
propel a feed forward cycle of neuronal cell death and inflammation underlying the 
progression of the disease  (Block and Hong, 2005). It has recently been recognised that 
individuals may present with a variety of neurological or psychiatric symptoms including 
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constipation, impaired olfaction, sleep disturbance, pain, depression and anxiety disorders 
which begin five and in some instances up to 20 years before the classical motor deficits of 
PD are apparent (Ferrer et al., 2011; Savica et al., 2010). While evidence from 
neuropathological studies and genomic analysis in AD suggests that defective inflammation 
is a preclinical event (Hoozemans et al., 2002; Bossers et al., 2010), to date there are no 
biomarkers for the detection of PD in the premotor phase. However, as both of these diseases 
present common features (protein aggregation, oxidative stress, progressive neuronal 
degeneration, systemic and neuroinflammation), and as there is now strong evidence for a 
relationship between inflammation and nigrostriatal degeneration, we surmise that targeting 
inflammatory events early in the disease progression, or indeed when possible during the 
premotor phase, will provide us with a promising therapeutic strategy for PD. 
 
2. Neuroinflammation in Parkinson’s disease 
Initial evidence of the involvement of inflammation in the progression of PD stems from a 
post-mortem study over twenty years ago, which demonstrated the presence of activated 
microglia in the SNpc of a PD patient (McGeer et al., 1988). Since then an abundance of 
clinical and animal studies supports the role of activated microglia and increased levels of 
inflammatory mediators such as cytokines, chemokines and ROS in the pathology of PD 
(Banati et al., 1998; Barcia et al., 2011; Boka et al., 1994; Cao et al., 2011; Crotty et al., 
2008; Depino et al., 2003; Dobbs et al., 1999; Hirsch and Hunot, 2009; Imamura et al., 2003; 
Long-Smith et al., 2010; Long-Smith et al., 2009; McGeer and McGeer, 2004; Mogi et al., 
1994a, b; Mount et al., 2007; Orr et al., 2002; Tansey et al., 2007). Enzymes associated with 
inflammation, such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-
2), have also been identified post-mortem in PD brains (Hunot et al., 1996; Knott et al., 
2000). Microglia become activated either directly due to a toxin, pathogen or endogenous 
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protein, or indirectly from dying neurons, and while mild activation of microglia has apparent 
beneficial effects, chronic microglial activation in response to neuronal damage as is evident 
in PD, results in the death of otherwise viable cells (Gao and Hong, 2008; Perry et al., 2010). 
Moreover, activation of microglia from dying neurons may be both long-lived and self-
propelling due to positive feedback from degenerating neurons even after the initial insult has 
ceased. This repetitive cycle of neurotoxic activation of microglia in response to neuronal 
damage is referred to as reactive microgliosis and is a feature of several brain pathologies 
such as AD, multiple sclerosis (MS), frontotemporal lobe dementia and PD (Block and Hong, 
2005). It is especially pertinent to PD because dopaminergic neurons in the SNpc are 
particularly susceptible to microglial-mediated neurotoxicity due to the high densities of 
microglia present (Kim et al., 2000). Thus, microglial activation and hence 
neuroinflammation is propagated to amplify the destruction of neurons in PD resulting in an 
accelerating feed-forward cycle of inflammation and neuronal death. 
 
Activated microglia release a host of inflammatory cytokines (interleukin (IL)-1β, IL-1 
receptor antagonist (IL-1RA), IL-6, IL-8, IL-10, IL-12, IL-18, tumour necrosis factor-α 
(TNF-α), interferon-gamma (IFN-,  macrophage colony stimulating factor), chemokines 
(macrophage inflammatory protein (MIP)-1α, MIP-1β, monocyte chemoattractant protein-1 
(MCP-1), Regulated upon activation, normal T cell expressed and secreted (RANTES)), and 
prostaglandins which can subsequently potentiate microglial activation through autocrine 
signalling to create a self-propagating cycle of expression (Kim and de Vellis, 2005). Pro-
inflammatory cytokines IL-1β, TNF-α, IL-2, IL-6 and IFN are constitutively expressed at 
basal levels in PD patients as demonstrated in post-mortem brains, serum and cerebrospinal 
fluid in vivo (Boka et al., 1994; Dobbs et al., 1999; Mogi et al., 1994a, b; Mount et al., 2007; 
Stypula et al., 1996). Moreover, the death signalling receptor TNF receptor type-1 (TNFR-1) 
9 
 
is expressed on dopaminergic neurons in human SNpc (Boka et al., 1994; Mogi et al., 2000). 
Animal studies support an involvement of these pro-inflammatory cytokines in the 
dopaminergic neuronal degeneration evident in PD; blockade of the soluble form of the TNF-
α receptor was found to attenuate the death of dopaminergic neurons in 6-hydroxydopamine 
(6-OHDA)- lesioned rats (McCoy et al., 2006), induction of chronic expression of IL-1β in 
adult rat SNpc using a recombinant adenovirus resulted in dopaminergic neuronal cell death 
starting only three weeks post-injection (Ferrari et al., 2006), and TNF could be detected in 
the SN of monkeys up to 14 years after administration of the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), (McGeer et al., 2003) suggesting that a chronic 
inflammatory state may be associated with progressive dopaminergic neurodegeneration. 
TNF, IL-1 and lipopolysaccharide (LPS) are also known to promote oxidative stress and 
accumulation of ROS (Fernandez-Checa et al., 1997; Nolan et al., 2003; Vereker et al., 
2001), the presence of which in the SN of PD patients plays a key role in dopaminergic 
neuronal death (Jenner et al., 1992; Jenner and Olanow, 1998; Mounsey and Teismann, 
2010). 
 
Substances which have been reported to be produced by dying dopaminergic neurons to 
activate microglia include α-synuclein-aggregates (Zhang et al., 2005), neuromelanin (Wilms 
et al., 2003), adenosine triphosphate (ATP) (Davalos et al., 2005) and matrix 
metalloproteinase-3 (MMP-3) (Kim et al., 2007a; Kim et al., 2005) (Figure 1). α-synuclein, 
the major constituent of Lewy bodies in PD, is nitrated by oxidative stress in the vicinity of 
dying dopaminergic neurons, which promotes aggregation of the protein. A growing body of 
evidence now suggests that nitrated, oxidised and aggregated α-synuclein released from 
dying dopaminergic neurons stimulates microglia and subsequent promotion of inflammation 
and oxidative stress (Croisier et al., 2005; Ischiropoulos and Beckman, 2003). α-synuclein 
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has been reported to be surrounded by activated microglia or inflammatory mediators in PD 
brains (McGeer et al., 1988; Yamada et al., 1992). It has also been shown to activate 
microglia in primary mesencephalic cultures and in mouse models of PD using adeno-
associated virus vectors to overexpress the protein (AAV2-SYN), both of which in turn 
amplify α-synuclein-mediated neurotoxicity (Zhang et al., 2005; Theodore et al., 2008). 
Moreover, the phagocytosis of extracellular aggregated α-synuclein by microglia has been 
shown to further activate microglia and propel dopaminergic neurodegeneration (Zhang et al., 
2005). Indeed a recent communication has identified glial cell-specific mitochondrial damage 
in a genetic mouse model of PD overexpressing doubly mutated human -synuclein (Schmidt 
et al., 2011), and suggest this as a potential mechanism underlying PD pathogenesis. These 
data suggest that the pathological modification of α–synuclein (overexpression or nitration as 
observed in PD) is sufficient to trigger neuroinflammation and consequently initiate the 
neurodegenerative process. However, the mechanism by which -synuclein activates and 
alters the function of microglia in PD is not yet understood although it has been shown from 
genomic and proteomic assays that nuclear factor-kappa B (NF-κB) plays a role (Reynolds et 
al., 2008) and more recently, Beraud et al suggested that alterations in the expression of toll-
like receptors (TLRs) are involved (Beraud et al., 2011).  Neuromelanin, a neuro-pigment 
released from stressed dopaminergic neurons has also been shown to induce microglial 
activation (Wilms et al., 2003). Its accumulation in human SNpc correlates with age 
progression, and extra neural melanin has been found in close proximity to activated 
microglial cells in patients suffering from juvenile idiopathic and MPTP-induced 
Parkinsonism (Ishikawa and Takahashi, 1998; Langston et al., 1999). Moreover, 
supplementation of microglial cultures with human neuromelanin in vitro has been shown to 
induce chemotactic effects and stimulate the release of TNF-α, IL-6 and nitric oxide (NO) 
(Wilms et al., 2003). Thus, the release of neuromelanin from dopaminergic neurons can 
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augment microglial activation and contribute to a self-perpetuating cycle of neuronal 
degeneration and chronic inflammation. Extracellular ATP, a purinergic neurotransmitter, 
was initially described as an activator of microglial cells (Kettenmann et al., 1993). The 
effects of ATP released from damaged neurons are mediated through its signalling with 
purinergic receptors, namely the metabotropic G-protein coupled P2Y receptors and the 
ligand gated ionotropic P2X receptors, both of which are expressed on microglia (Butt, 
2011). Along with other pro-migratory factors such as extracellular uridine-5'-triphosphate 
(UTP) and members of the chemokine family, ATP facilitates the migration of microglia 
along a chemotactic gradient to the site of injury or inflammation from damaged cells. ATP 
then interacts with P2 receptors on microglia to stimulate the release of TNF-α, IL-1β, iNOS 
and NO (Davalos et al., 2005). Experiments by Kim et al have identified a pivotal role for the 
protease MMP-3 released from degenerating dopaminergic neurons in microglial activation 
(Kim et al., 2005). 1-methyl-4-phenylpyridinium (MPP+)-stressed primary mesencephalic 
dopaminergic neurons induce and release active MMP-3, which is toxic to dopaminergic 
neurons themselves. In addition, treatment of mesencephalic neuron-glia mixed cultures with 
catalytically active recombinant MMP-3 has been reported to stimulate microglial cell 
activation, superoxide generation and  to enhance dopaminergic neuronal cell death, while 
MMP-3-/- mice did not exhibit microglial activation, superoxide generation or dopaminergic 
degeneration after MPTP administration (Kim et al., 2007a).  
 
While numerous factors are known to activate microglia, it has been postulated that microglia 
can also be maintained in a quiescent state by various micro-environmental inhibitory 
influences, many of which are produced by neurons. Hence, microglial activation during 
pathological insult may be due to a “switching-off” of these inhibitory neuronal signals 
(Ransohoff and Cardona, 2010).  One such neuron-cell inhibitory signalling mechanism is the 
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direct cell-to-cell interactions between neuronal-CD200 (OX2) and its receptor CD200R, 
expressed on microglia. The CD200-CD200R interaction is essential for maintaining 
microglial homeostasis in the unperturbed CNS. A down-regulation of CD200 expression has 
been observed in neurons exposed to inflammatory conditions, and inhibition of CD200 
causes microglial activation (Lyons et al., 2007). Therefore, there is a direct neuronal 
mechanism for regulating microglial activity, and loss of this interaction during neuronal cell 
degeneration may stimulate up-regulation of CD200, facilitating microglial activation. We 
and others have provided recent evidence to implicate the impairment of CD200-CD200R 
interaction as a contributing factor in PD neurodegeneration (Bieschke et al., 2011; Miller et 
al., 2011). Blockade of CD200R was shown to selectively and significantly enhance 
dopaminergic neuronal cell susceptibility to rotenone and iron-induced neurotoxicity in 
mesencephalic neuron-glia co-cultures. This was coupled with elevated microglial activation 
and superoxide generation and a decrease in CD200 expression on dopaminergic neurons 
(Bieschke et al., 2011). Microglia have also been shown to receive inhibitory inputs from a 
neuronal membrane-tethered chemokine CX3CL1, through its receptor CX3CR1, and removal 
of this inhibition also unleashed microglial activity (Shan et al., 2011). Other inhibitory 
signals exist between CD22-CD45, CD172A-CD47 and ICAM5-LFA-1 (Ransohoff and 
Perry, 2009). 
 
3. Systemic inflammation and Parkinson’s disease  
It has been proposed that in TBI such as cerebral ischaemia or in chronic neurodegenerative 
diseases like PD, systemic infections and inflammation can exacerbate symptoms and 
promote damage (Denes et al., 2010; Perry et al., 2007). Following infection or injury, a 
systemic immune response ensues comprising both acquired immunity and innate immunity. 
During the initial innate response, peripheral monocytes, and resident tissue macrophages 
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secrete pro-inflammatory cytokines IL-1β, TNF and IL-6 as well as prostaglandins and 
chemokines, which contribute to the behavioural and metabolic components that induce 
sickness behaviour (Ferrari and Tarelli, 2011; Perry et al., 2007). Through autocrine 
signalling these cytokines induce self-synthesis and the synthesis of further cytokines 
(Dantzer, 2009) which can affect the brain via several routes; by interaction with the vagus 
nerve (Tracey, 2002), by activating endothelial cells and perivascular macrophages 
(Laflamme et al., 1999) and through circumventricular organs which lack a functional blood-
brain barrier (BBB) (Blatteis, 1992). Cytokines like TNF-α can then stimulate microglia to 
secrete chronically elevated pro-inflammatory mediators, which in turn can induce chronic 
self-perpetuating neuroinflammation, resulting in a slow and progressive loss of 
dopaminergic neurons in the SNpc (Qin et al., 2007). It has been proposed that the brain 
recognises cytokines as molecular signals of sickness, and induces symptoms of malaise, 
lassitude, fatigue, anhedonia, apathy, numbness, coldness, and reduced appetite and body 
temperature (Dantzer, 2009; Perry et al., 2007). To reinforce this theory, it has been 
demonstrated that a systemic inflammatory challenge in an animal model of chronic 
neurodegeneration exhibits exaggerated brain inflammation, sickness behaviour, cognitive 
changes and an acceleration of neurodegeneration (Cunningham et al., 2009; Perry et al., 
2007). This emerging “two-hit hypothesis” in the aetiology of neurodegenerative diseases 
such as PD, suggests that the disease is multifactorial, and possibly a consequence of 
“multiple-hits” involving a variety of inflammatory stimuli (Di Monte, 2003). Infectious 
agents may comprise the first “hit”, therefore sensitising the brain to subsequent “hits”, 
which may not have been pathogenic in the absence of an already “primed” system (Jang et 
al., 2009a). In this instance, microglia in the aged or diseased brain are said to be “primed” 
and can evoke an exaggerated response contributing to disease progression (Perry et al., 
2007). Another interesting “two-hit hypothesis” is that proposed by Hawkes and co-workers 
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who suggest that -synuclein aggregation is triggered in olfactory structures and in enteric 
nerves during the premotor phase of PD (which may contribute to premotor symptoms 
including constipation and impaired olfaction), and then spreads slowly over time to other 
brain regions (Hawkes et al., 2007). They suggest that a neurotropic virus may be 
responsible, but given the evidence of the pathological relationship between -synuclein 
aggregation, inflammation and nigrostriatal degeneration, it is tempting to speculate that 
systemic inflammation may be a strong contender for investigation as a culprit during the 
premotor phase of PD. 
 
3.1 Epidemiological evidence 
Epidemiological reports suggest a correlation between systemic inflammatory events, chronic 
neuroinflammation and the aetiology and progressive nature of PD (Ferrari and Tarelli, 2011; 
Long-Smith et al., 2009; Perry, 2010). Associations were first established towards the end of 
the first world war (1924-1918) when the H1N1 influenza-A pandemic was coupled with a 
dramatic increase in post-encephalitic Parkinsonism (PEP) (also referred to as “sleeping 
sickness” or von Economo encephalitis) (Jang et al., 2009a; Rail et al., 1981; Tansey et al., 
2007). People born during this time were at a 2-3 fold increased risk of developing PD, with 
PEP implicated in 50% of all Parkinsonism cases (Jang et al., 2009a; Tansey et al., 2007).  
PEP shares cardinal symptomatology with idiopathic PD including rigidity and bradykinesia 
but a lack of Lewy body formation (Jang et al., 2009a). Moreover, Takahashi et al., 1995 
demonstrated that the H1N1 virus preferentially targets the SNpc, the primary site of 
pathology in PD (Takahashi et al., 1995). It has also been shown that exposure to the highly 
pathogenic neurotropic H5N1 influenza virus increases susceptibility to developing PD with 
an observed onset of post-influenzal encephalopathies (Jang et al., 2009b). Other viruses 
associated with secondary Parkinsonism include coxsackie virus (Poser et al., 1969; Walters, 
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1960), Japanese encephalitis B (Ogata et al., 1997), St. Louis virus (Pranzatelli et al., 1994), 
west Nile virus (Robinson et al., 2003) and human immunodeficiency virus (HIV) (Tse et al., 
2004). Infection with Japanese-encephalitis virus (JEV), which occurs predominantly in 
India, China and Southeast Asia, for a prolonged period is likely to induce PEP (Ogata et al., 
2000; Shoji et al., 1993; Tansey et al., 2007). People with JEV have similar 
neuropathological and locomotor symptoms to patients with idiopathic PD (Tansey et al., 
2007), and the virus has previously been used to create a pre-clinical model of PD in rats 
(Ogata et al., 1997). This group demonstrated that in Fisher rats infected with JEV, there was 
marked gliosis and dopaminergic neuronal loss in the SNpc similar to that seen in PD, and 
bradykinesia which could be reversed with L-3,4-dihydroxyphenylalanine (L-DOPA) and 
monoamine oxidase (MAO) inhibitors. More recently, in a cohort of 60 JEV patients, 
transient-type Parkinsonian features were observed in 16 patients, with 19 displaying 
Parkinsonism with additional dystonia (Misra and Kalita, 2010). Pathological and clinical 
evidence has also identified the involvement of the gastrointestinal tract in enhancing 
susceptibility to idiopathic Parkinsonism, with Helicobacter pylori infection proposed as a 
potential trigger in disease progression (Tansey and Goldberg, 2010; Weller et al., 2005). 
Indeed, polymorphisms in the nucleotide-binding oligiomerization domain 2 (NOD2) gene 
associated with Crohn’s disease, a chronic inflammatory bowel disease, have been shown to 
be over-represented in patients with idiopathic PD (Bialecka et al., 2007).  
 
3.2 Blood Brain Barrier permeability 
As alluded to above, a disruption in neurovascular homeostasis with increased BBB 
permeability and infiltration of systemic inflammatory mediators into the brain has been 
identified as a contributing factor to the pathology of several neurological diseases including 
PD (Hemmer et al., 2004; Rite et al., 2007; Stolp and Dziegielewska, 2009). Indeed, positron 
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emission tomography (PET) and histological studies of PD patients as well as MPTP and 
LPS-induced models of PD reveal a pathogenic link between neuroinflammation, increased 
BBB permeability and the consequent infiltration of systemic inflammatory molecules, and 
dopaminergic neuronal death (Chung et al., 2010). It is also likely that inflammatory 
mediators infiltrate the brains of PD patients due to the fact that efflux pumps that regulate 
BBB permeability are operating at reduced function in PD patients (Kortekaas et al., 2005) or 
that blood vessels are dysfunctional in in the midbrain of PD patients (Faucheux et al., 1999). 
Moreover, activated microglia have an up-regulated expression of cellular adhesion 
molecules, and the subsequent induction of chemokine gradients direct peripheral leucocytes 
to the site of inflammation (Chung et al., 2010; Stone et al., 2009a; Tansey and Goldberg, 
2010). An increased level of the vasculogenic and angiogenic protein, vascular endothelial 
growth factor (VEGF) has been demonstrated in PD patients and in the MPTP model (Yasuda 
et al., 2007). Likewise, another report provides evidence that nigral injection of VEGF to 
mice disrupted the BBB permeability and induced dopaminergic neuronal death in the ventral 
mesencephalon (VM) (Chen et al., 2008a). Acute systemic injection of LPS to rats either 
directly or indirectly can also cause functional breakdown of the BBB resulting in 
granulocyte infiltration and activation of parenchymal microglia (Banks and Robinson, 2010; 
Laflamme et al., 1999; Laflamme and Rivest, 1999; Perry, 2004) which contribute to the 
degeneration of dopaminergic neurons in the SNpc (Brochard et al., 2009; Dutta et al., 2008). 
Although LPS at high concentrations is used in animals to model sepsis (Mannel, 2007), to 
date there has only been one report of Parkinsonism as a neurological complication of sepsis; 
Alasia et al (2006) reported a case of a Nigerian male who developed Parkinsonism-like 
symptoms on a background of gram-negative sepsis which were resolved with antibiotic 
therapy (Alasia et al., 2006). 
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3.3 T Lymphocytes 
Assessment of serum obtained from PD subjects demonstrates a role for an adaptive immune 
response in PD (Hirsch and Hunot, 2009). Increased levels of CD4+ T-cells have been 
reported in the serum of patients with PD, suggesting peripheral activation of lymphocytes 
(Bas et al., 2001; Fiszer et al., 1994; Hirsch and Hunot, 2009). Infiltrating cytotoxic CD4+ 
and CD8+ T-cells, but not B-cells, have also been observed in the inflamed SNpc of post-
mortem PD human specimens and in the MPTP-induced mouse model of PD during the 
course of neurodegeneration (Brochard et al., 2009; Ferrari and Tarelli, 2011; Stone et al., 
2009a). In support of a specific role for systemic immune cells in the degeneration of nigral 
dopaminergic neurons, CD4-/- mice have been shown to be resistant to MPTP-induced 
neurotoxicity in the SNpc (Brochard et al., 2009), while Benner and co-workers demonstrate 
that mice deficient in T and B-lymphocytes were more resistant to MPTP (Benner et al., 
2008). In addition, this group also report that nitrated α-synuclein was detected in the lymph 
nodes of MPTP-treated mice where it was associated with increased expression of the class II 
major histocompatibility complex. They further show that nitrated -synuclein can also cross 
the BBB, enter cervical lymph nodes, activate antigen presenting cells (APCs) and stimulate 
naïve T-cells to expand into subsets of CD4+ and CD8+ effector T-cells. Mice immunised with 
a nitrated fragment of α–synuclein displayed strong T-cell and pro-inflammatory responses 
whereas the native protein did not elicit an immune response. Furthermore, the response to 
nitrated α–synuclein led to an increased neuroinflammatory response and accelerated 
neurodegeneration following treatment with MPTP. The influence of -synuclein on the 
adaptive immune response and consequently on the neuroinflammatory response was also 
reported by Theodore et al. who showed that four and twelve weeks after an AAV2-SYN 
injection, mice displayed increased CD-68 positive microglia and increased infiltration of B 
and T-lymphocytes in the SN of injected animals compared to controls. In addition, the levels 
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of pro-inflammatory cytokines were elevated compared to controls (Theodore et al., 2008). 
These studies implicate that the adaptive immune system contributes to the progression and 
pathogenesis of PD (extensively reviewed by (Cao et al., 2011) and indicate that this 
promising line of investigation (which will be further discussed below as a potential 
immunomodulatory therapy) warrants additional work to determine definitive targets for PD 
therapies. 
 
3.4 Systemic Cytokines 
Amplified levels of the cytokines TNF-α, IL-2, IL-6 and RANTES (Brodacki et al., 2008; 
Dobbs et al., 1999; Rentzos et al., 2007; Stypula et al., 1996) have also been detected in 
serum obtained from PD patients. It has been proposed that increases in these serum cytokine 
levels may serve as a therapeutic marker for PD, based on a blood sample study of men with 
high plasma concentrations of IL-6 correlating with an increased risk of developing PD 
(Chen et al., 2008b). Increased serum levels of soluble TNFR-1 were also detected in PD 
patients, which is in agreement with an earlier study showing elevated TNFR-1 in the SNpc 
of PD brains (Mogi et al., 2000), although this was not associated with clinical parameters. 
Another group however, has demonstrated that an LPS-induced increase of MCP-1, 
RANTES, MIP-1α, IL-8, IL-6 and IFNγ levels secreted by peripheral blood mononuclear 
cells significantly correlated with the severity of PD symptoms (Reale et al., 2009). In 
support of the role of primed microglia, in the “two-hit hypothesis”, a low level of systemic 
inflammation induced by a non-toxic dose of LPS has been shown to increase the severity of 
nigral dopaminergic neuronal cell loss in response to a subsequent low-dose of 6-OHDA in 
the rat model of PD (Koprich et al., 2008), while chronic systemic IL-1 also exacerbated 
neurodegeneration and microglial activation in the SNpc of 6-OHDA-treated rats (Pott 
Godoy et al., 2008).   
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3.5 Prenatal Systemic Infection 
Evidence now suggests that prenatal systemic infections may be a risk factor for the 
development of PD in later life. It has been suggested that prenatal infections such as 
bacterial vaginosis (BV) in humans may be potential risk factors for PD (Ling et al., 2002). 
Indeed, during pregnancy, levels of LPS and TNF-α are elevated in the chorioamniotic 
environment of women with BV (Menon et al., 1995; Okada et al., 1997), and evidence from 
animal studies have demonstrated that prenatal inflammagen exposure may hinder typical 
dopaminergic neuron development. In a study by Ling et al, brains from postnatal day (P) 21 
rat pups born to dams that were intraperitoneally injected with LPS at the gestation window 
of vulnerability (embryonic day (E) 10.5), displayed reduced numbers of tyrosine 
hydroxylase (TH) immunoreactive cells in the SNpc and ventral tegmental area. This 
apparent dopaminergic neuronal loss was associated with reduced striatal dopamine and an 
increase in TNF-α in the striatum and mesencephalon when examined at P21. (Ling et al., 
2002). It is likely that dopaminergic neurons are lost at the time of embryonic exposure of 
LPS, as reports from studies examining the effect of treatment with LPS or pro-inflammatory 
cytokines IL-1 and TNF on TH immunoreactivity in embryonic mesencephalic cultures in 
vitro have revealed that these immunomodulatory agents reduce dopaminergic neuronal 
viability (Bronstein et al., 1995; Jarskog et al., 1997; Long-Smith et al., 2010). Another group 
has reported the loss of dopaminergic neurons up to 16 months post exposure of rats to LPS 
in utero, which corresponds to the mean age in humans at which PD symptoms are first 
observed, and they have suggested that prenatal exposure of rats to LPS is a potential model 
of PD as it induces a slow, protracted loss of nigral dopaminergic neurons (Carvey et al., 
2003). Further validation for this model was demonstrated by significant dopamine and 
serotonin reductions observed in the frontal cortex, nucleus accumbens, striatum, amygdala, 
hippocampus and hypothalamus, comparable to the neurochemical alterations evident in PD 
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subjects (Wang et al., 2009). More recently however, suggestions of prenatal endotoxin 
exposure to rats as a progressive animal model of PD have been thwarted by a study 
demonstrating that prenatal LPS exposure to rats does not accelerate dopaminergic neuronal 
loss but rather that the progressive dopaminergic neuronal loss observed in these rats is due to 
normal aging (Ling et al., 2009). This group had previously carried out a study to examine 
the effect of prenatal exposure to systemic inflammation on the progression of dopaminergic 
neuronal loss induced by 6-OHDA at a later stage. In this study, prenatally LPS-exposed rats 
were subjected to a moderate dose of 6-OHDA at four-months and the data revealed that both 
prenatal LPS exposure and postnatal 6-OHDA-treatment produced significant dopaminergic 
neuron loss. However, the combined effect was additive and not synergistic. This may have 
been due to the young age of the animal or the toxin used (Ling et al., 2004). This model was 
subsequently investigated but with prenatally LPS-exposed rats treated with rotenone rather 
than 6-OHDA postnatally. The combined effects of LPS and rotenone produced a synergistic 
loss of TH+ cells in the SNpc relative to controls, which was associated with increased 
striatal-dopamine activity, TNF-α and increased reactive microglia (Ling et al., 2004). To 
mimic a response to viral rather than a bacterial infection, challenges with polyriboinosinic-
polyribocytidilic acid (Poly I:C), a TLR-3 agonist and synthetic analogue of double-stranded 
RNA have been used in rats. Results have revealed an increase in the production of pro-
inflammatory cytokines in the brain (Cunningham et al., 2007) , an exacerbation of chronic 
neurodegeneration (Field et al., 2010), and an induction of nigrostriatal dopaminergic 
neurodegeneration in adult rats (Deleidi et al., 2010). When administered early in gestation to 
mice, acute poly I:C induced maternal immune activation and a subsequent increase in the 
numbers of dopaminergic neurons in the foetal brains during middle and late foetal 
development (Meyer et al., 2008a). This is in contrast to studies reporting that prenatal 
challenge with bacterial LPS induced a reduction in the numbers of dopaminergic neurons 
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postnatally, and suggests that the source of infection and immune activation may have a 
specific impact on dopaminergic neuronal development, or indeed that there is a gestational 
window of susceptibility to immunological challenge. This hypothesis that the timing of 
prenatal exposure to maternal infection is critical for dopaminergic neuronal development 
was tested by the same group who showed that early but not late foetal exposure of mice to 
poly I:C challenge reduced prefrontal dopamine D1 receptors in adulthood (Meyer et al., 
2008b). The impact of the timing of prenatal viral exposure on the development and later 
viability of dopaminergic neurons in the adult nigrostriatal pathway has yet to be explored. 
 
4. Neuroinflammatory diagnostic tools for Parkinson’s disease 
Microglial responsiveness to injury and neurodegenerative disease suggests that it may serve 
as a marker for the diagnosis and progression of disease pathology in PD. Thus there is a 
current drive to develop non-invasive imaging tools to assess and quantify the dynamics of 
activated microglia in neurodegenerative diseases like PD. Advances in this technology, 
especially for identification of microglial biomarkers at the early stages of disease, would 
have important implications for PD diagnosis, assessment of progression, and therapy. 
Currently, the best-studied imaging paradigm for microglial activation is the radiolabelled 
translocator protein (TSPO) ligand using PET (Dolle et al., 2009). This line of research 
initially started when a correlation was observed between increased binding of Ro5-4864 (a 
benzodiazepine) and PK11195 (an isoquinoline) to receptors on the surface of mitochondria 
primarily localised in glial cells (Arlicot et al., 2008; Chauveau et al., 2008). These receptors 
were originally referred to as peripheral type benzodiazepine receptors and were increased in 
activated microglia (Park et al., 1996; Stephenson et al., 1995). The nomenclature has since 
been changed to TSPO as further research elucidated that these receptors are expressed 
throughout the brain and body (Papadopoulos et al., 2006). Gene-expression analysis in 
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brains of rodents, primates and humans have illustrated that TSPO expression is nearly absent 
in parenchyma-microglia (Winkeler et al., 2010) but is elevated in many neurodegenerative 
disorders including, stroke, AD, PD, MS, Huntington’s disease (HD) and amyotrophic lateral 
sclerosis (ALS), (Arlicot et al., 2008), thus emphasising the involvement of microglial 
activation and neuroinflammation in these diseases. As TSPOs are the prototypical 
biomarkers of neuroinflammatory changes in a variety of CNS disorders, they have therefore 
been proposed as potential diagnostic targets for in vivo imaging (Arlicot et al., 2008; 
Chauveau et al., 2008).  
 
Currently, functional PET and single photon emission tomography (SPECT), in conjunction 
with ligands for TSPO, can detect microglial activation in vivo. Examples of radiolabelled 
TSPO ligands include [11C]Ro5-4864 and [11C](R)-PK11195 (1-(2-chlorophenyl)-N-methyl-
N-(1-methylpropyl)-3 isoquinoline carboxamide) (Chauveau et al., 2008). In PD subjects, 
PET imaging revealed microglial activation in the pons, basal ganglia, and frontal and 
temporal cortical areas, and longitudinal studies of these patients revealed stable [11C](R)-
PK11195 binding potential (BP; a parameter that mixes receptor density with ligand affinity), 
indicative of early activation of microglia in PD pathology (Gerhard et al., 2006; Winkeler et 
al., 2010). However, the [11C](R)-PK11195 tracer is limited, as it is incapable of 
distinguishing between phenotypic differences, and thus possibly functional differences of 
microglia. To overcome this, a PET tracer for the dopamine-transporter (DAT), [11C]CFT, 
has been used in conjunction with [11C](R)-PK11195 to examine the viability of the 
presynaptic dopaminergic neurons (Ouchi et al., 2009). This study of 10 drug-naïve PD 
patients, demonstrated changes in microglial activity in conjunction with DAT density which 
were investigated using PET imaging with [11C](R)-PK11195 and [11C]CFT tracers. Subjects 
underwent magnetic resonance imaging (MRI) prior to PET measurement to define the 
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regions of interest, which would allow for the evaluation of microglial activation in parallel 
with presynaptic neuronal degeneration in vivo. Elevated midbrain [11C](R)-PK11195 BP 
levels were significantly inversely correlated with [11C]CFT BP localised in the putamen, and 
the elevated [11C](R)-PK11195 BP also correlated with motor impairment. A follow-up 4-
year scan revealed increased microglial activation spread over the extrastriatal region (Ouchi 
et al., 2009). PET imaging and post-mortem analysis of the brain of a rat lesioned with 6-
OHDA revealed reduced [11C]CFT BP in the striatum, indicative of dopaminergic 
degeneration, while [11C](R)-PK11195 BP was markedly increased in the striatum and SNpc. 
Post-mortem immunohistochemical analysis corroborated this finding by showing activated 
microglia in the striatum and SNpc at 4 weeks post-lesion (Cicchetti et al., 2002). Alternative 
SPECT imaging biomarkers for TSPO such as [123I]CLINDE (2-(4′iodophenyl)-3-(N,N-
diethyl)-imidazo[1,2-a]pyridine-3-acetamide) have been examined in vivo and also pose as 
potential image-guided diagnostic tools for microglial activation in neurodegenerative 
diseases like PD (Arlicot et al., 2008).  
 
5. Immunomodulatory therapies 
As the wealth of evidence from animal models continues to accumulate regarding the 
apparent role of inflammation in the pathogenesis of PD, a large number of inhibitory drugs 
have been investigated (Table 2). The use of broad spectrum steroidal and non-steroidal anti-
inflammatory drugs (NSAIDs), specific microglial inhibitors or anti-inflammatory cytokines 
have not only helped decipher the role of microglial activation in neuroinflammation in PD 
but also indicated that inhibiting the specific processes involved in microglial activation may 
be a therapeutic avenue for PD.  
 
5.1 Glucocorticoids 
24 
 
The glucocorticoids are well known for their broad range of anti-inflammatory effects and 
have long been used in clinical settings for the treatment of brain inflammation (Castano et 
al., 2002). Microglial cells express the glucocorticoid receptor, which is involved in the 
regulation of the transcription factor NF-κB and activator protein-1 (AP-1) (Scheinman et al., 
1995), which in turn are key regulators of pro-inflammatory cytokine expression (Nadeau and 
Rivest, 2003). Of particular interest, the synthetic steroid dexamethasone was shown to 
provide neuroprotection against LPS or MPTP-induced toxicity in rodent models. In both 
models, the delivery of dexamethasone prevented the activation of microglia usually 
associated with neurodegeneration (Castano et al., 2002; Kurkowska-Jastrzebska et al., 
2004). However, the severe side-effects associated with glucocorticoid use prevent any long-
term usage in neuroprotective therapies for PD. Large scale epidemiological studies have 
shown that the chronic use of NSAIDs such as aspirin or ibuprofen could provide some level 
of protection against PD (Chen et al., 2005; Chen et al., 2003; Kurkowska-Jastrzebska et al., 
2006; Mohanakumar et al., 2000). Other studies suggest that the role of NSAIDs in 
decreasing the risk of PD is extremely limited (Hancock et al., 2007; Hernan et al., 2006). A 
recent meta-analysis of studies published between 1966 and 2008 showed that while NSAIDs 
as a class do not modify the risk of developing PD, the chronic intake of ibuprofen may have 
a beneficial effect (Gagne and Power, 2010; Gao et al., 2011; Samii et al., 2009). Ibuprofen 
possibly mediates this effect via its inhibition of COX activity to inhibit the production of 
pro-inflammatory lipid mediator prostaglandins (Mitchell et al., 1993). Some of the beneficial 
effects observed could also be mediated via other mechanisms associated with NSAIDs such 
as inactivation of the pro-inflammatory nuclear receptor NF-κB (Grilli et al., 1996; Kopp and 
Ghosh, 1994), activation of peroxisome proliferator-activated receptor gamma (PPARγ), a 
nuclear factor mediating anti-inflammatory effects in microglia (Bernardo et al., 2005) or 
activation of the Rho kinase pathway (Zhou et al., 2003). Results from animal models of PD 
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demonstrate that aspirin and indomethacin have both been shown to prevent MPTP-induced 
loss of striatal dopamine in the mouse (Aubin et al., 1998; Kurkowska-Jastrzebska et al., 
2002). The NSAID Celecoxib reversed striatal dopaminergic neuronal fibre and nigral 
dopaminergic neuronal cell loss in 6-OHDA-treated rats (Sanchez-Pernaute et al., 2004) 
while aspirin has been shown to prevent 6-OHDA-induced striatal dopamine depletion (Di 
Matteo et al., 2006). 
 
5.2 Minocycline 
Other neuroimmunomodulatory strategies include the use of the second generation 
tetracycline analogue, minocycline. It has been shown to inhibit microglial activation and 
prevent iNOS and nicotinamide adenine dinucleotide phosphate-oxidase (NADPH-oxidase) 
generation as well as IL-1β up-regulation (Du et al., 2001). It is a lipophilic molecule which 
easily crosses the BBB and is reported to have anti-inflammatory and neuroprotective 
activities (Kim and Suh, 2009). Some studies in experimental models of PD have shown that 
it is neuroprotective against MPTP-, LPS, or 6-OHDA-induced neurodegeneration (Du et al., 
2001; He et al., 2001; Quintero et al., 2006; Tomas-Camardiel et al., 2004; Wu et al., 2002) 
while others showed that it exacerbated the deleterious effects of MPTP in rodents and non-
human primates (Diguet et al., 2004; Yang et al., 2003). While the reason for the 
discrepancies is unknown, differences between the various studies include doses and timing 
of intervention and may reflect the dual role of microglia in inflammation. Indeed, results of 
clinical trials from various patient cohorts suffering neurological diseases have also revealed 
differing results; significant toxicity was found after a phase III randomised trial in patients 
with ALS (Gordon et al., 2007),  a phase III futility study in HD recommended that further 
study of minocycline in HD was not warranted (Schwarz et al., 2010), while  the results of a 
double-blind, placebo-controlled study have suggested the beneficial effects of minocycline 
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as a combination therapy for MS (Metz et al., 2009), and another preliminary study showed 
efficacy in acute ischemic stroke (Lampl et al., 2007). Despite these contradictory results, a 
phase II randomized double-blind futility clinical trial of minocycline in PD has been set-up. 
Results after 12 and 18 months suggest that minocycline is well tolerated and does not 
negatively impact on symptomatic treatment. It is therefore currently recommended for phase 
III clinical trials to assess its long-term effect on disease progression (NINDS-NET-PD-
Investigators, 2006, 2008). 
 
5.3 Regulatory T cells 
One of the mechanisms whereby the immune response can be modulated to prevent the 
prolonged cytotoxic effects of inflammation on endogenous tissue involves regulatory T-cells 
(Tregs), and it is currently under investigation as a potential target for immunomodulatory 
therapies for PD and other neurological disorders including ALS and CNS injury (for reviews 
see Appel et al., 2010; Walsh and Kipnis, 2011).  Tregs are capable of inhibiting an immune 
response by suppressing CD4+ and CD8+ effector T-cells (Teffs) and B-cell responses, 
counteracting the actions of myeloid and APCs, including microglia, and promoting release 
of anti-inflammatory IL-10 and TGF-. They also promote neurotrophic factor production 
(brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor 
(GDNF)) from astrocytes (for review see Qian et al., 2010; Stone et al., 2009b) suggesting a 
capacity of Tregs for promotion of dopaminergic neuronal cell development.  A number of 
studies by Reynolds and co-workers have demonstrated that Treg alters the microglial 
response in response to nitrated -synuclein (Reynolds et al., 2009a, b). Specifically, 
CD4+CD25+ Treg were shown to suppress nitrated -synuclein microglial-induced ROS and 
NF-B activation, while CD4+CD25- Teffs exacerbated microglial activation and induced 
neurotoxic responses (Reynolds et al., 2009a). This group also show that Treg alters the 
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microglial proteome in response to nitrated -synuclein and suggest that this mechanism of 
Treg-mediated microglial response can slow the momentum and course of PD (Reynolds et 
al., 2009b). Interestingly, the neuropeptide vasoactive intestinal peptide (VIP), which is a 
potent inducer of Treg (Delgado et al., 2005), has been reported to prevent MPTP-induced 
loss of nigral dopaminergic neurons and striatal dopaminergic fibres in the mouse, while also 
down-regulating IL-1β and TNF-α expression and iNOS generation (Delgado and Ganea, 
2003). In a more recent study, the adaptive immune response and nigrostriatal dopaminergic 
neurodegeneration generated as a result of immunization of MPTP-treated mice with nitrated 
-synuclein was attenuated by VIP-induced Tregs (Reynolds et al., 2010). This effect was 
mediated in part through Tregs suppression of Th17-mediated inflammatory response and the 
mechanism has been proposed as a potential immunisation strategy for PD (Cao et al., 2011; 
Reynolds et al., 2010). Thus manipulating this adaptive response by redirecting the harmful 
T-cell response towards an anti-inflammatory and protective immune response by means of 
an antigen-based immunisation could be a successful approach for neuroprotection in PD. 
Preclinical results using glatiramer acetate (a random amino acid polymer composed of 
alanine, glutamine, lysine and tyrosine amino acids, also known as copolymer 1 and 
copaxone) as an immunisation agent showed that this approach could be successful. 
Glatiramer-acetate primed T-cells transferred to MPTP-treated mice were shown to reach the 
brain where they suppressed microglial activation and provided neuroprotection to the 
nigrostriatal neurons by inducing the neurotrophic factor GDNF. Furthermore, specific 
depletion of the donor T-cells abrogated this neuroprotective effect confirming that the effect 
is donor T-cell dependent (Benner et al., 2004). Moreover, the donor T-cells were shown to 
secrete high levels of anti-inflammatory cytokines IL-4, IL-10 and TGF-β (Benner et al., 
2004). Interestingly, there is also evidence to suggest that glatiramer acetate is an inducer of 
Tregs (Arnon and Aharoni, 2004). As glatiramer acetate has already been shown to be safe 
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and tolerable in clinical trial and has had significant reduction effects on disability in MS 
patients (Comi et al., 2011), it represents a very attractive possibility. The complex 
interactions between infiltrating lymphocytes, glial cells and neurons is not fully elucidated 
and further research is necessary for the development and advance of novel effective adaptive 
cell-based therapies for PD. However, if the above results are indicative of outcomes that 
could be achieved through Treg based therapeutics, then the future for neuroprotection in PD 
is encouraging.  
 
5.4 Cytokines 
Alternatively, the delivery of anti-inflammatory cytokines such as IL-10 could be considered 
as an anti-inflammatory therapeutic strategy for PD. Pre-treatment of mesencephalic 
neuroglial cultures with IL-10 inhibited LPS-stimulated microglial activation and 
degeneration of dopaminergic neurons (Qian et al., 2006). Similar neuroprotective effects 
were observed in vivo after chronic infusion of IL-10 into the SNpc of rats that were 
challenged with LPS (Arimoto et al., 2006). More recently, gene therapy approaches have 
been developed to deliver IL-10 into the rat SNpc, and have proved effective in attenuating 
the neuronal loss and behavioural deficits in the 6-OHDA rat model of PD (Johnston et al., 
2008). It has been suggested that targeted delivery of IL-10 such as by gene delivery to CNS 
tissue in order to maintain effective levels of the cytokine over a sustained period of time 
would yield more effective results in progressive neurological disorders such as MS or PD 
(O'Garra et al., 2008). This reasoning has come about due to the lack of efficacy as well as 
the pro-inflammatory and cytotoxic effects of systemic administration of IL-10 in clinical 
studies for patients with psoriasis, Crohn’s disease and rheumatoid arthritis (Asadullah et al., 
2003; Lauw et al., 2000; Tilg et al., 2002), and from preclinical studies showing that 
experimental autoimmune encephalomyelitis mice (a model of MS) intracerebrally injected 
29 
 
with an adenovirus inducing expression of IL-10 in the brain can inhibit disease pathology 
(Cua et al., 2001). Thus, the potential of targeted delivery of anti-inflammatory cytokines like 
IL-10 to CNS tissue for the treatment of brain inflammation and the consequent associated 
neurological deficits is ripe for exploration. Furthermore, the blockade of pro-inflammatory 
cytokines should be considered as a potential therapeutic avenue. Blocking the soluble TNF 
signalling by delivery of a dominant-negative form has been shown to promote neuronal 
survival and reduce the behavioural deficits in the hemi-Parkinsonian rat model of PD 
(McCoy et al., 2006; McCoy et al., 2008). While these pre-clinical results are interesting, the 
availability of a broad spectrum of compounds acting on TNF signalling makes this molecule 
a very attractive target. Etanercept and Infliximab are a new generation of engineered 
inhibitors of TNF that are broadly used for the treatment of rheumatoid arthritis and other 
peripheral inflammatory diseases. Their use in CNS diseases is however limited by their 
general inability to cross the BBB (Tweedie et al., 2007). While direct intrastriatal delivery or 
long-term gene transfer as illustrated above are possibilities, other inhibitors of TNF 
synthesis may prove useful such as the infamous antiemetic compound thalidomide. 
Thalidomide is a sedative, immunosuppressive and anti-inflammatory drug that has 
teratogenic effects (Smithells and Newman, 1992) and inhibits the synthesis of TNF-α 
(Sampaio et al., 1991). Thalidomide was shown to protect nigrostriatal neurons and prevent 
striatal dopamine depletion in the early stages of MPTP-induced neurodegeneration (Boireau 
et al., 1997; Ferger et al., 2004). 
 
As mentioned above, NF-κB plays an important role in the regulation of chronic diseases 
through the promotion of inflammation and of cell survival. Activated NF-κB (which requires 
the activity of the IκB kinase (IKK) complex (Kim et al., 2006)) has been detected in neurons 
and activated microglia in the SNpc of PD patients and MPTP-treated animals suggesting that 
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some of the pro-inflammatory mechanisms regulated by the NF-κB pathways may play an 
important role in the pathogenesis of PD (Ghosh et al., 2007; Hunot et al., 1997). Recent 
studies have shown that blockade of NF-κB activity either directly or through IκB can inhibit 
components of the inflammatory pathways in microglia namely, the oxidative stress pathway 
and the production of pro-inflammatory cytokines (Anrather et al., 2006; Gauss et al., 2007). 
Selective inhibition of NF-κB activity by a peptide blocking the IKK complex prevented 
dopaminergic neuronal loss in MPTP-treated mice and suppressed microglial activation 
(Ghosh et al., 2007). Finally, a selective pharmacological IKKβ inhibitor has demonstrated 
neuroprotective properties in LPS- and MPTP-induced models of PD. Treatment with this 
compound prevented neuronal damage in a process dependant on the presence of microglia. 
Particularly, it prevented the activation of microglial oxidative pathways and the release of 
pro-inflammatory cytokines by specific blockade of the NF-κB signalling pathway (Zhang et 
al., 2010).  
 
5.5 PPAR 
PPAR has been shown to exert anti-inflammatory functions in both the periphery and the 
CNS where it is detected in glial and neuronal cells. Following activation by its naturally 
occurring ligands eicosanoids and prostaglandin J2, it regulates the expression of pro-
inflammatory molecules such as iNOS, COX-2, and indirectly of a broad array of cytokines 
through its interactions with the transcription factor NF-κB (Chaturvedi and Beal, 2008; 
Chung et al., 2008). Pioglitazone and rosiglitazone are two synthetic agonists of PPARγ that 
are approved for the treatment of type II diabetes. In the CNS they exhibit neuroprotective 
effects in models of neurodegenerative disorders, including PD, by preventing inflammation, 
oxidative damage and apoptosis (Chaturvedi and Beal, 2008). Specifically, pioglitazone 
prevents MPTP-induced activation of microglia and dopaminergic neuronal cell loss in 
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murine SNpc in vivo (Dehmer et al., 2004). This has been shown to occur through inhibition 
of monoamine oxidase B (MAO-B), the enzyme responsible for conversion of MPTP to its 
toxic metabolite MPP+ (Quinn et al., 2008). When pioglitazone was administered to rats that 
were also injected intrastriatally with LPS, the resultant LPS-induced microglial activation 
and dopaminergic degeneration was attenuated (Hunter et al., 2007). Recently, the 
neuroprotective effects of rosiglitazone have been shown in the MPTP mouse model of PD; 
chronic administration of the drug prevented behavioural deficits, dopaminergic neuronal loss 
and microglial activation in the SNpc in vivo (Schintu et al., 2009). 
 
2-adrenoceptor agonists 
Noradrenaline (NA) is a neurotransmitter which is present throughout the body and is known 
to elicit anti-inflammatory actions in the brain by stimulating glial 2-adrenoceptors.  For 
instance, NA suppresses production of neurotoxic substances including TNF-, IL-1 and 
NO from activated microglia (Feinstein et al., 2002; McNamee et al., 2010a).  In fact, NA 
plays a key role in keeping brain microglia in a quiescent state, and loss of NA sensitises the 
brain to inflammatory damage (Heneka et al., 2003, 2010). The locus coeruleus (LC) is the 
primary source of NA cell bodies and their axons innervate almost all parts of the brain 
including the SN and striatum, and LC cell numbers are reduced by approximately 60% at 
autopsy in PD patients compared to normal age-matched controls (Marien et al., 2004). 
Consequently, NA inputs into the SN are depleted in the brains of PD patients (Gesi et al., 
2000), and it has been suggested that loss of LC NA neurons is a significant contributor to the 
progression of PD, and that pharmacotherapies aimed at restoring normal NA tone are likely 
to have therapeutic potential (Rommelfanger and Weinshenker, 2007). The idea that NA loss 
contributes significantly to pathology in PD is supported by the observation that depletion of 
NA exacerbates DA loss in animal models of PD including the MPTP and 6-OHDA models 
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(Fornai et al., 2007).  It has also been demonstrated that treatment with NA reuptake 
inhibitors (NRIs); a class of drugs that enhance availability of the neurotransmitter NA, the 
endogenous ligand for 2-adrenoceptors in the CNS  inhibit microglial activation and 
production of inflammatory mediators TNF- and NO, and inhibit activation of NF-B 
(O'Sullivan et al., 2009), and that treatment with 2-adrenoceptor agonists elicits anti-
inflammatory and neuroprotective effects in the CNS (Gleeson et al., 2010; McNamee et al., 
2010a, b).  Moreover, a recent report indicates that 2-adrenoceptor agonists inhibit 
dopaminergic neuron loss induced by LPS in vitro and in vivo (Qian et al., 2011). In further 
support of the idea that NRIs may be successful in ameliorating the progression of PD, it has 
been demonstrated that NA transporter knockout mice display reduced toxicity to MPTP 
(Rommelfanger et al., 2004). In this regard, both NRIs and 2-adrenoceptor agonists are 
lipophillic compounds and readily penetrate the CNS.  Moreover, long-term treatment with 
NRIs represent a clinically feasible neuroprotective strategy in PD, as these agents are 
currently used in the treatment of depression and attention deficit hyperactivity disorder, and 
clinical data demonstrates that these agents are safe when taken for prolonged periods.  
Similarly, long-acting 2-adrenoceptor agonists are already in widespread therapeutic use for 
the treatment of asthma and chronic obstructive airway disease (COPD). 
 
5.7 microRNAs and RNA interference 
Although microRNAs (miRNAs) are expressed in the brain, only a limited number of studies 
have examined the biological role of miRNAs in brain disorders including PD (Hebert and 
De Strooper, 2007; Saugstad, 2010). These small RNA molecules (21-23 nucleotides) are 
non-protein coding transcripts that play an important function in post-transcriptional 
regulation of gene expression in the development, function and survival of mammalian 
midbrain dopaminergic neurons, and so their expression may be a potential therapeutic 
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marker for disease progression of PD. For example, miR-133b, which is specifically 
expressed in midbrain dopaminergic neurons, is deficient in patients with PD and it has also 
been shown to regulate the maturation and function of midbrain dopaminergic neurons within 
a negative feedback circuit that includes the transcription factor Pitx3 (Kim et al., 2007b). 
MiR-7 which is expressed mainly in neurons binds to the α-synuclein mRNA 3’-UTR to 
repress protein expression and therefore protect cells against oxidative stress. Analysis of the 
MPTP model of PD indicates decreased expression of miR-7, which results in elevated α-
synuclein expression (Junn et al., 2009). Single nucleotide polymorphisms within the 
fibroblast growth factor 20 gene disrupts a binding site for miR-433, resulting in increased 
fibroblast growth factor 20 and subsequent α-synuclein expression (Wang et al., 2008). It is 
feasible then to suggest that miRNAs that regulate inflammatory mediators such as cytokines, 
which are participating players in the progression of PD, may contribute to the pathogenesis 
of sporadic PD. For instance, recent work by Bauer and colleagues have shown that a miR-
30-based shRNA construct (which can activate cellular immune responses) prevented IFN-
stimulated gene expression of oligoadenylate synthetase 1 (Oas1) and was concomitant with 
accelerated apoptosis and neuronal loss (Bauer et al., 2009). Thus, it would be interesting to 
investigate the role of miR-30 in inflammation-induced changes in dopaminergic neuronal 
development and survival. Ultimately, miRNAs may be a potential therapeutic target for PD, 
although the practicalities of manipulating miRNAs as therapeutic targets may yet be a long 
way from the clinic. 
 
A relatively recent technological advance which is considered an attractive therapeutic option 
for the treatment of CNS diseases is RNA interference. This post-transcriptional gene 
silencing mechanism allows for selective and efficient gene silencing which can be used for 
functional analysis of individual genes. Small interfering RNA (siRNA) is now widely 
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applied in mammalian cell cultures and in animal models of CNS disorders (Paddison et al., 
2002; Thakker et al., 2006). Thus in PD research, the advent of RNA interference is a 
prospective useful approach for silencing target genes to increase our understanding of 
dopaminergic cell mechanisms, provide us with potential therapeutic targets for manipulation 
of genes in vivo, or in cultured cells for transplantation to the brain (Porras and Bezard, 
2008). For example, using an in vitro model of PD, Yang and colleagues have previously 
demonstrated that the application of siRNA against protein kinase Cδ (PKCδ) abolished the 
MPP+- induced PKCδ activation, DNA fragmentation and dopaminergic neuronal cell loss 
(Yang et al., 2004). More recently, it has been reported that siRNA directed against -
synuclein and infused into the SNpc of primates caused a significant reduction in nigral -
synuclein expression (McCormack et al., 2010). Considering that inflammation in the host 
brain is a contributing factor to the progression of dopaminergic neuronal demise as well as 
to the functional outcome of neural transplantation procedures in PD (Piccini et al., 2005), it 
is conceivable that silencing of host or transplanted inflammatory mediators using RNA 
interference is a therapeutic avenue which is worthy of investigation. 
 
6. Conclusion 
Although the precise role of inflammation in the pathogenesis of PD remains unclear, an 
array of evidence from the clinic and from animal models now points to its involvement in 
fuelling progression of the disease. Moreover, the assertion that both systemic and central 
inflammation contributes to the demise of nigral dopaminergic neuronal function is rapidly 
gaining momentum. Therefore, in order to develop strategies to counteract the consequences 
of inflammation on the susceptible Parkinsonian brain, it is essential that research is 
undertaken to better understand how the brain and systemic immune system communicate, as 
well as to decipher the fundamental mechanisms of how dopaminergic neuronal cells die in 
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an inflammatory environment. The immunomodulatory approaches described here show both 
limitations and promise for therapeutics for PD. For example, Tregs currently show particular 
promise in light of the fact these cells can promote the development of dopaminergic neurons 
and so have potential in cell replacement strategies, as well as the fact that they have shown 
capacity to form the basis of immunisation strategies. We hypothesise that the emerging 
information on the role of the immune system in PD, especially early in the disease 
progression will provide us with a window of opportunity to target early symptoms of this 
debilitating disease. 
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Table 1: 
Inflammatory processes involved in Parkinson’s disease 
Process Location Reference 
Activated 
microglia 
Brain (Banati et al., 1998; Imamura et al., 2003; McGeer et al., 
1988; Sawada et al., 2006) 
COX-2 Brain (Knott et al., 2000) 
IFN-γ Brain (Mogi et al., 2007; Reale et al., 2009) 
IL-1β Brain/CSF (Blum-Degen et al., 1995; Hunot et al., 1996; Mogi et al., 
1994a) 
IL-2 Brain/Serum (Mogi et al., 1996; Stypula et al., 1996) 
IL-6 Brain/Serum/CSF 
 
(Blum-Degen et al., 1995; Dobbs et al., 1999; Mogi et al., 
1994a; Muller et al., 1998; Reale et al., 2009) 
IL-8 Serum (Reale et al., 2009) 
iNOS Brain (Hunot et al., 1996; Knott et al., 2000) 
MCP-1 Serum (Reale et al., 2009) 
MIP1- α Serum (Reale et al., 2009) 
RANTES Serum (Reale et al., 2009; Rentzos et al., 2007) 
TNF-α Brain/Serum/CSF (Boka et al., 1994; Dobbs et al., 1999; Hunot et al., 1996; 
Mogi et al., 1994b) 
TNF-R1 Brain (Boka et al., 1994; Mogi et al., 2000) 
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Table 2: 
Anti-inflammatory agents in animal models of Parkinson’s disease 
Agent Mode of action Species 
PD 
model 
Effects References 
Dexamethasone SAID Mouse MPTP 1. Prevented striatal DA depletion Kurkowska-Jastrzebska 
et al., 2004 
    2. Protected DA neurons in SN  
  Rat LPS 1. Prevented striatal DA depletion Castano et al., 2002 
    2. Protected dopaminergic neurons in SN  
Aspirin NSAID Mouse MPTP Prevented striatal DA depletion Aubin et al., 1998 
  Rat 6-
OHDA 
Prevented striatal dopamine depletion Di Matteo et al., 2006 
Salicylic acid NSAID Mouse MPTP 1. Attenuated akinesia and catalepsy Mohanakumar et al., 
2000 
    2. Prevented DA depletion and changes 
in DA turnover in nucleus caudatus 
putamen 
 
Ibuprofen NSAID Mouse MPTP 1. Partially prevented striatal DA 
depletion 
Kurkowska-Jastrzebska 
et al., 2006 
Indomethacin NSAID Mouse MPTP 1. Prevented striatal DA depletion  Kurkowska-Jastrzebska 
et al., 2002 
    2. Protected DA neurons in SN  
Celecoxib NSAID Rat 6-
OHDA 
Reversed striatal DA neuronal fibre and 
nigral DA neuronal cell loss 
Sanchez-Pernaute et al., 
2004 
Minocycline Microglial 
activation inhibitor 
Mouse MPTP 1. Protected DA neurons in SN  Du et al. 2001; Wu et 
al., 2002 
    2. Prevented DA depletion in thestriatum 
and nucleus accumbens 
 
  Rat 6-
OHDA 
1. Reduced apomorphine-induced 
rotations  
He et al., 2001; 
Quintero et al., 2006 
    2. Protected DA neurons in SN  
  Rat LPS Protected dopaminergic neurons in SN Tomas-Camardiel et al., 
2004 
Interleukin-10 Anti-inflammatory 
cytokine 
Rat LPS Protected DA neurons in SN Arimoto et al., 2006 
 Rat 6-
OHDA 
1. Protected dopaminergic neurons in SN  Johnston et al., 2008 
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    2. Prevented striatal DA depletion  
    3. Reduced apomorphine-induced 
rotation 
 
Pioglitazone PPARγ agonist Mouse MPTP Protected DA neurons in SN Dehmer et al., 2004 
  Rat LPS 1. Prevented striatal DA depletion  Hunter et al., 2007 
    2. Protected DA neurons in SN  
Rosiglitazone PPARγ agonist Mouse MPTP 1. Prevented errors in beam traversal test  Schintu et al., 2009 
    2. Protected DA neurons in SN  
    3. Partially prevented striatal DA 
depletion 
 
Glatiramer acetate Immunisation Mouse MPTP 1. Prevented striatal DA depletion Benner et al., 2004 
    2. Protected DA neurons in SN  
Vasoactive intestinal 
peptide 
Anti-inflammatory 
molecule 
Mouse MPTP 1. Protected DA neurons in SN Delgado and Ganea, 
2003 
   2. Protected striatal DA fibres  
Thalidomide TNF inhibitor Mouse MPTP 1. Prevented striatal DA depletion Boireau et al., 1997; 
Ferger et al., 2004 
    2. Protected DA neurons in SN  
IKK inhibitor Blockade of NF-κB 
signalling 
Rat LPS 1. Protected DA neurons in SN Zhang et al., 2010 
 
Nisoxetine 
 
NA transporter 
inhibitor 
Mice MPTP 1.Protected DA neurons in Striatum Rammelfanger et al., 
2004 
Salmeterol β-2-adrenoceptor 
agonist 
Mice LPS 
MPTP 
1.Inhibits LPS-induced microglial 
activation 
Qian et al., 2011 
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Figure 1. Microglial activation and dopaminergic neuronal damage. Schematic 
representation of the impact of microglial activation (induced by injury, environmental 
toxins, endogenous proteins, infection or age) on dopaminergic neuronal deterioration 
through the release of inflammatory mediators, and the consequent precipitating effect of 
substances released from dying dopaminergic neurons on microglial activation. 
 
 

